lifestyle.pluralist.com

Author: Rgenta Therapeutics

Rgenta Therapeutics Announces Two Oral Presentations Highlighting Proprietary RSwitch Technology at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting

April 27, 2026
Rgenta Therapeutics Announces RGT-61159 Clinical Poster Presentation at the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

April 21, 2026
Rgenta Therapeutics Presents Preclinical Data, Unveiling its New Drug Candidate, RGT-0474060, as a Promising Oral PMS1 Inhibitor for the Treatment of Huntington’s Disease

February 25, 2026